tiprankstipranks
Agios Pharma (CH:8AP)
:8AP
Switzerland Market
8AP
Agios Pharma
RESEARCH TOOLSreports

Agios Pharma (8AP) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

8AP Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
6 Buy
3 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Agios
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

8AP Stock 12 Month Forecast

Average Price Target

―
Based on 9 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is CHF33.50 with a high forecast of CHF44.57 and a low forecast of CHF25.12. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF44.57Average Price TargetCHF33.50Lowest Price TargetCHF25.12
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on CH:8AP
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (NASDAQ: GEHC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Agios Pharma (NASDAQ: AGIO)
TD Cowen Analyst forecast on CH:8AP
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)
Citi Analyst forecast on CH:8AP
Samantha Semenkow
Citi
Citi
CHF37.28→CHF42.14
Buy
―
Reiterated
07/31/26
Agios Pharmaceuticals price target raised to $52 from $46 at CitiAgios Pharmaceuticals price target raised to $52 from $46 at Citi
H.C. Wainwright Analyst forecast on CH:8AP
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
CHF42.14→CHF44.57
Buy
―
Reiterated
07/30/26
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. WainwrightAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
Bank of America Securities Analyst forecast on CH:8AP
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF37.28
Buy
―
Reiterated
07/30/26
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
RBC Capital Analyst forecast on CH:8AP
Luca Issi
RBC Capital
RBC Capital
CHF25.93
Hold
―
Reiterated
07/30/26
RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO)
Goldman Sachs Analyst forecast on CH:8AP
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF25.93
Hold
―
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)
Leerink Partners Analyst forecast on CH:8AP
Andrew Berens
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)
J.P. Morgan Analyst forecast on CH:8AP
Tessa Romero
J.P. Morgan
J.P. Morgan
CHF29.17→CHF25.12
Hold
―
Assigned
06/11/26
Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on CH:8AP
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (NASDAQ: GEHC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Agios Pharma (NASDAQ: AGIO)
TD Cowen Analyst forecast on CH:8AP
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)
Citi Analyst forecast on CH:8AP
Samantha Semenkow
Citi
Citi
CHF37.28→CHF42.14
Buy
―
Reiterated
07/31/26
Agios Pharmaceuticals price target raised to $52 from $46 at CitiAgios Pharmaceuticals price target raised to $52 from $46 at Citi
H.C. Wainwright Analyst forecast on CH:8AP
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
CHF42.14→CHF44.57
Buy
―
Reiterated
07/30/26
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. WainwrightAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
Bank of America Securities Analyst forecast on CH:8AP
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF37.28
Buy
―
Reiterated
07/30/26
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
RBC Capital Analyst forecast on CH:8AP
Luca Issi
RBC Capital
RBC Capital
CHF25.93
Hold
―
Reiterated
07/30/26
RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO)
Goldman Sachs Analyst forecast on CH:8AP
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF25.93
Hold
―
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)
Leerink Partners Analyst forecast on CH:8AP
Andrew Berens
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)
J.P. Morgan Analyst forecast on CH:8AP
Tessa Romero
J.P. Morgan
J.P. Morgan
CHF29.17→CHF25.12
Hold
―
Assigned
06/11/26
Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
DNLIDenali Therapeutics
SNDXSyndax Pharmaceuticals
ZYMEZymeworks
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agios Pharma

3 Months
Marc FrahmTD Cowen
Success Rate
16/23 ratings generated profit
70%
Average Return
+4.52%
Copying Marc Frahm's trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +4.52% per trade.
1 Year
Gregory RenzaTruist Financial
Success Rate
18/30 ratings generated profit
60%
Average Return
+15.20%
Copying Gregory Renza's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +15.20% per trade.
2 Years
Gregory RenzaTruist Financial
Success Rate
20/30 ratings generated profit
67%
Average Return
+12.80%
Copying Gregory Renza's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +12.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8AP Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
7
7
6
4
2
Buy
11
15
20
18
13
Hold
5
8
7
6
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
30
33
28
18
In the current month, 8AP has received 15 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 8AP average Analyst price target in the past 3 months is 33.50.
Each month's total comprises the sum of three months' worth of ratings.

8AP Financial Forecast

8AP Earnings Forecast

Next quarter’s earnings estimate for 8AP is -CHF0.99 with a range of -CHF1.29 to -CHF0.73. The previous quarter’s EPS was -CHF1.38. 8AP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.
Next quarter’s earnings estimate for 8AP is -CHF0.99 with a range of -CHF1.29 to -CHF0.73. The previous quarter’s EPS was -CHF1.38. 8AP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.

8AP Sales Forecast

Next quarter’s sales forecast for 8AP is CHF43.78M with a range of CHF38.24M to CHF52.89M. The previous quarter’s sales results were CHF36.41M. 8AP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.
Next quarter’s sales forecast for 8AP is CHF43.78M with a range of CHF38.24M to CHF52.89M. The previous quarter’s sales results were CHF36.41M. 8AP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.

8AP Stock Forecast FAQ

What is CH:8AP’s average 12-month price target, according to analysts?
Based on analyst ratings, Agios Pharma’s 12-month average price target is 33.50.
    What is CH:8AP’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:8AP, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Agios Pharma a Buy, Sell or Hold?
        Agios Pharma has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.
          What is Agios Pharma’s share price target?
          The average share price target for Agios Pharma is 33.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF44.57 ,and the lowest forecast is CHF25.12. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Agios Pharma?
            Agios Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
              How can I buy shares of Agios Pharma?
              To buy shares of CH:8AP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.